If you have been reading about 强制降解 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-15. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Lebanese historian Philip K. Hitti commented on the relationship between the Druze and Christians in Lebanon, noting: "Folty Comte, a French scholar, was astonished by the remarkable similarity between the Druze and the Maronites (Christians) in their way of life, system of governance, dialect, customs, and public morals. Druze and Maronite families coexist harmoniously, and sometimes Maronites accompany their Druze neighbors to church". According to Hitti, the Druze believe in the efficacy of holy water blessed by a priest, and occasionally, if a missionary persists in evangelizing the Druze, they may accept the sacrament of baptism. Maretti, an Italian monk who visited the region in 1760, just before Folty's arrival, observed that the Druze show genuine affection and respect for Christians and their religion. He also noted that Druze pray in Greek Orthodox churches as they do in Turkish mosques. Historian Ray Jabre Mouawad observes that during the Ottoman period, there existed religious symbiosis between the Druze and Christians in Mount Lebanon. This period saw numerous cultural interactions, leading to shared symbols, the veneration of common saints, and the adoption of common terminology to refer to God. Evidence of these interactions can be found in the palaces and mausoleums of Druze leaders, as well as in Maronite and Greek Orthodox churches. According to scholar Pierre-Yves Beaurepaire, due to the Christian influence on the Druze faith, two Christian saints become the Druze's favorite venerated figures: Saint George and the Prophet Elijah.
Cosmetics are regulated by the Center for Food Safety and Applied Nutrition, the same branch of the FDA that regulates food. Cosmetic products are not, in general, subject to premarket approval by the FDA unless they make "structure or function claims" that make them into drugs (see Cosmeceutical). However, all color additives must be specifically FDA approved before manufacturers can include them in cosmetic products sold in the U.S. The FDA regulates cosmetics labeling, and cosmetics that have not been safety tested must bear a warning to that effect. According to the industry advocacy group, the American Council on Science and Health, though the cosmetic industry is primarily responsible for its own product safety, the FDA can intervene when necessary to protect the public. In general, though, cosmetics do not require pre-market approval or testing. The ACSH says that companies must place a warning note on their products if they have not been tested, and that experts in cosmetic ingredient review also play a role in monitoring safety through influence on ingredients, but they lack legal authority. According to the ACSH, it has reviewed about 1,200 ingredients and has suggested that several hundred be restricted—but there is no standard or systemic method for reviewing chemicals for safety, or a clear definition of what 'safety' even means so that all chemicals get tested on the same basis.
To enable this construct to be used in a subsequent reaction as an entry vector, the MoClo and Golden Braid standards were designed. The MoClo standard involves defining multiple tiers of DNA assembly:
PCP is both water- and lipid-soluble and is therefore distributed throughout the body quickly. PCP is metabolized into PCHP, PPC and PCAA. The drug is metabolized 90% by oxidative hydroxylation in the liver during the first pass. Metabolites are glucuronidated and excreted in the urine. Nine percent of ingested PCP is excreted in its unchanged form. When smoked, some of the compound is broken down by heat into 1-phenylcyclohexene (PC) and piperidine. The time taken before the effects of PCP manifest is dependent on the route of administration. The onset of action for inhalation occurs in 2–5 minutes, whereas the effects may take 15 to 60 minutes when ingested orally.
Sources: en.wikipedia.org
== One Health approach == Antimicrobial resistance (AMR) is commonly described within a One Health framework, which emphasizes the interconnected relationships between human health, animal health, and the environment. Antimicrobial use in clinical medicine, veterinary practice, and agriculture has been associated with the selection and spread of resistant microorganisms across these sectors. Research indicates that resistant bacteria and antimicrobial resistance genes can move between humans, animals, and environmental reservoirs through multiple pathways, including food production systems, direct contact, and exposure to contaminated water or soil. These pathways contribute to the persistence and wider dissemination of antimicrobial resistance beyond individual settings. Environmental sources have been increasingly examined in relation to AMR. Wastewater systems, agricultural runoff, and pharmaceutical residues have been identified as potential reservoirs where resistant microorganisms and resistance genes may persist. Such reservoirs may facilitate ongoing transmission between environmental, animal, and human populations. Efforts to address AMR within a One Health framework typically involve coordinated strategies across sectors, including antimicrobial stewardship, infection prevention and control, and improvements in sanitation and hygiene.
=== 1970s === Recombinant DNA technology emerged in the 1970s, fundamentally transforming biomedical research. In 1972 and 1973, Paul Berg, Herbert Boyer, and Stanley Cohen developed techniques to cut and splice DNA molecules from different organisms, establishing the foundation of modern biotechnology. In 1975, Georges Kohler and Cesar Milstein developed hybridoma technology to produce monoclonal antibodies, creating highly specific tools for diagnostic assays and targeted therapies. The late 1970s also witnessed major public health milestones, including the global eradication of smallpox, certified by the World Health Organization in 1979, and the introduction of Fred Sanger's DNA sequencing method in 1977.
== Discovery == The parent structure of lefetamine, 1,2-diphenylethylamine was first synthesized in the 1940s and showed weak analgesic activity. Lefetamine itself was first investigated in Japan in the 1950s. The L-isomer showed weak analgesic action comparable to codeine and antitussive action far weaker than codeine. The d-isomer showed no such activity but caused seizures in rats.
=== 5α-Reductase inhibition === Progesterone is a substrate for 5α-reductase, and has been found to act as a competitive inhibitor of this enzyme in vitro in a variety of studies. In one study, it showed IC50Tooltip half-maximal inhibitory concentration values of 1,375 nM and 88 nM (in the presence of 50 nM androstenedione as the substrate) for 5α-reductase types 1 and 2, respectively. 5α-Reductase is highly expressed in skin, hair follicles, and prostate gland, and is responsible for the transformation of testosterone into the several-fold more potent androgen DHT in such tissues. As such, it has been suggested that progesterone might possess some antiandrogenic effect via acting as a 5α-reductase inhibitor. However, inhibition of 5α-reductase by progesterone is described as a weak effect that has only been demonstrated in vitro and at supraphysiological concentrations. In accordance, physiological levels of circulating progesterone have not been found to importantly influence circulating DHT concentrations. Congenital 5α-reductase 2 deficiency is a rare intersex condition which is associated with ambiguous genitalia in male fetuses due to a deficiency in DHT production during genital differentiation. Experimental prenatal exposure to established 5α-reductase inhibitors like finasteride has been found to produce similar feminized genital defects in male animals including rodents and monkeys. In contrast, exogenous administration of progesterone to pregnant rodents and monkeys has resulted in minimal abnormality in either male or female pups.
=== December === December 1 – COVID-19 pandemic: In California, the first case of Omicron variant, a highly mutated variant of COVID-19, is reported by the CDC in a San Francisco resident, who had traveled to South Africa. December 2 Major League Baseball begins a lockout of its players. It is their first lockout since 1990. COVID-19 pandemic: Minnesota reports their first case of Omicron variant. Two Georgia election officials, Ruby Freeman and Wandrea' ArShaye Moss, file a defamation lawsuit against The Gateway Pundit. The lawsuit is the first to be filed by individual election workers who were targeted during the 2020 presidential election. December 4 – Chris Cuomo is fired by CNN for his violations of journalistic ethics by aiding his scandal-ridden brother. December 9 Workers at a Starbucks in Buffalo, New York vote 19–8 to unionize, becoming the first Starbucks in the country to do so. A virtual summit, Summit for Democracy, was hosted by the United States "to renew democracy at home and confront autocracies abroad". December 10 – A late season tornado outbreak occurs in the Southern and Midwestern United States, causing major damage and killing at least 94 people. December 11 COVID-19 pandemic: North Carolina reports its first case of the Omicron variant in a student at UNC Charlotte. The MLS Cup 2021 hosted in Portland, Oregon, New York City FC defeated Portland Timbers after won 4–2 on penalties (Both teams drew 1–1 in regulation and extra time).
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.